(Total Views: 635)
Posted On: 02/23/2021 11:48:40 PM
Post# of 148903
Sometimes I think I'm really smart & sometimes I think I'm not. I often think I'm just slow. So I'm studying this RLFTF PR stuff today. And wondering how many of my statements below are accurate and how a PR can be "created" to bring about a soaring 30% share price with news of a failed Primary Endpoint?
1) In the RLFTF Phase 2b/3 Trial, they missed their Primary Endpoint with a
p value 0.08? (So, we'd expect share price to plunge! Unless, it can be spun?)
2) Big Huge Letter Headline touting a result as if they've achieved breakthru success: NeuroRx Announces that ZYESAMI™ (Aviptadil) has Successfully Demonstrated 10-Day Accelerated Recovery from Respiratory Failure in Critically Ill Patients with Covid-19? Misleading hype of a Secondary Endpoint?
3) Subtitle reads: NeuroRx to File for Emergency Use Authorization in This Patient Population if Positive Results Continue to be Demonstrated at Day-60 Endpoint in Line with FDA's New Guidance" ("If" "If" "If" @ day 60.....well of course they would file for an EUA "If"....)
4) In the PR today, there was "intentionally" no mention that the p value of 0.08 was for their Primary Endpoint. No mention that Primary Endpoint was not met.
Stating: " Should these trends continue through day 60, they have the potential to reach statistical significance." ("spin", potential "If"....)?
5) RLF-100 "demonstrated multidimentional benefit around its prespecified Primary Endpoint". What is that? Is that gooblygock "we found some benefi but missed it" ???
6) Rather than disclose the failure, the spin was to appear optimistic in that the drug "demonstrated multidimentional benefit".....and, because the FDA recently amended some ot the timing protocal, their trial 28 day data will be re-evaluated at the end of 60 days, for a possible adequate p value???
7) The PR spin and convenient no mention of the p value of Primary Endpoint being missed then can be perceived as positive, created a soaring 30% rise in the share price. By late afternoon, some day traders took profits, and some investors eventually realized the PR was not genuine, so they went from 30% rise in share price, back down to 14%.
1) In the RLFTF Phase 2b/3 Trial, they missed their Primary Endpoint with a
p value 0.08? (So, we'd expect share price to plunge! Unless, it can be spun?)
2) Big Huge Letter Headline touting a result as if they've achieved breakthru success: NeuroRx Announces that ZYESAMI™ (Aviptadil) has Successfully Demonstrated 10-Day Accelerated Recovery from Respiratory Failure in Critically Ill Patients with Covid-19? Misleading hype of a Secondary Endpoint?
3) Subtitle reads: NeuroRx to File for Emergency Use Authorization in This Patient Population if Positive Results Continue to be Demonstrated at Day-60 Endpoint in Line with FDA's New Guidance" ("If" "If" "If" @ day 60.....well of course they would file for an EUA "If"....)
4) In the PR today, there was "intentionally" no mention that the p value of 0.08 was for their Primary Endpoint. No mention that Primary Endpoint was not met.
Stating: " Should these trends continue through day 60, they have the potential to reach statistical significance." ("spin", potential "If"....)?
5) RLF-100 "demonstrated multidimentional benefit around its prespecified Primary Endpoint". What is that? Is that gooblygock "we found some benefi but missed it" ???
6) Rather than disclose the failure, the spin was to appear optimistic in that the drug "demonstrated multidimentional benefit".....and, because the FDA recently amended some ot the timing protocal, their trial 28 day data will be re-evaluated at the end of 60 days, for a possible adequate p value???
7) The PR spin and convenient no mention of the p value of Primary Endpoint being missed then can be perceived as positive, created a soaring 30% rise in the share price. By late afternoon, some day traders took profits, and some investors eventually realized the PR was not genuine, so they went from 30% rise in share price, back down to 14%.
(5)
(0)Scroll down for more posts ▼
